MIRAE ASSET

MedTech

Results Comment February 7, 2019

(Maintain)		Buy			
Target Price (12M,	W)	22	2,000		
Share Price (02/01/	19, W)	15	5,400		
Expected Return			43%		
OP (18F, Wbn) Consensus OP (18F	, Wbn)		21 23		
EPS Growth (18F, % Market EPS Growth P/E (18F, x) Market P/E (18F, x) KOSDAQ		16.1 5.3 16.0 9.2 716.92			
Market Cap (Wbn) Shares Outstanding Free Float (%) Foreign Ownership Beta (12M) 52-Week Low 52-Week High		256 17 30.0 4.6 0.82 12,750 21,600			
(%) Absolute Relative	1M -5.8 -11.2	6M -21.8 -13.8	12M -28.0 -8.8		



Mirae Asset Daewoo Co., Ltd.

[MedTech/Healthcare Solutions]

Choong-hyun Kim, CFA +822-3774-1740 choonghyun.kim@miraeasset.com

Rayence (228850 KQ)

Poised for both revenue growth and margin improvement in 2019

4Q18 review: Below-consensus results

For 4Q18, Rayence reported revenue of W27.5bn (+6% YoY), below the consensus, weighed by sluggish sales of dental (+4% YoY) and medical (-20.1% YoY) products. That said, growth was strong in the industrial (+66.1% YoY) and veterinary (+189.5% YoY) segments. Operating profit came in at W4bn (+7.5% YoY; OP margin of 14.6%), far below the consensus. Operating expenses remained largely unchanged QoQ, but slower top-line growth led to higher cost pressures.

Successful revenue diversification; exposure to Vatech down to 35%

1) Dental: In the dental detector segment, Rayence has been diversifying its customer base beyond Vatech since 2018. Specifically, the company has reportedly won a five-year contract worth W49bn from a Chinese customer. We look for additional revenue growth going forward. Rayence has become the world's no. 1 intraoral sensor maker (23% market share), building upon its status as the only supplier of bendable intraoral sensors. We expect the company to begin generating meaningful global ODM sales in 2019.

2) Industrial: Rayence, which offers both TFT (lower pricing) and CMOS (high resolution) detectors, is diversifying its product (tires, batteries, PCB, semiconductor, rechargeable batteries, etc.) and customer portfolios. We expect the company to expand its market share, especially in Europe and Asia.

3) Veterinary: Rayence recently acquired a veterinary electronic medical record supplier and a drugs distributor to expand its veterinary business beyond diagnostic equipment (X-rays, CTs, oral sensors, etc.). The veterinary business, which operated at a loss during its expansion, should turn a profit in 2019, contributing to overall earnings improvement.

4) Medical: In the company's core market of retrofit X-ray systems, ASP has continued to decline due to intensifying competition. Rayence is focusing on driving sales volume through expansion into Latin America via its subsidiary Osko, B2B contracts with GE Healthcare, and a technology transfer deal in Brazil. In particular, we anticipate Osko to turn a profit on volume growth in 2019, supporting overall earnings improvement.

Maintain Buy and TP of W22,000

We maintain our Buy rating and target price of W22,000 on Rayence. The stock currently trades at a 12-month forward P/E of 11.6x, a discount to global peers (14.8x). Rayence is continuing top-line growth by diversifying its business portfolio (exposure to Vatech has declined from 40% in 2015 to 35% in 2018) using its robust CMOS and TFT technologies. While OP margin is above 20% on a non-consolidated basis, margins have come under pressure due to subsidiary losses. In 2019, we expect the company's subsidiaries to swing to a profit, leading to margin improvements. We look for meaningful earnings improvement in 2019.

FY (Dec.)	12/15	12/16	12/17	12/18F	12/19F	12/20F
Revenue (Wbn)	87	98	107	116	134	147
OP (Wbn)	20	18	17	21	26	30
OP margin (%)	23.0	18.4	15.9	18.1	19.4	20.4
NP (Wbn)	14	15	15	17	22	25
EPS (W)	1,150	947	881	1,023	1,312	1,486
ROE (%)	27.3	13.1	8.5	9.4	11.2	11.4
P/E (x)	-	18.1	21.0	16.0	11.7	10.4
P/B (x)	-	1.7	1.7	1.4	1.2	1.1
Dividend yield (%)	-	1.7	0.5	0.6	0.6	0.6

Note: All figures are based on consolidated K-IFRS; NP refers to net profit attributable to controlling interests Source: Company data, Mirae Asset Daewoo Research estimates

Analysts who prepared this report are registered as research analysts in Korea but not in any other jurisdiction, including the U.S. PLEASE SEE ANALYST CERTIFICATIONS AND IMPORTANT DISCLOSURES & DISCLAIMERS IN APPENDIX 1 AT THE END OF REPORT.

(Wbn, %, %p)

(Wbn, W, %)

Table 1. 4Q18 review

				4Q18P	Growth		
	4Q17	3Q18	Preliminary	Mirae Asset Daewoo	Consensus	YoY	QoQ
Revenue	25.9	29.7	27.5	30.3	30.2	6.0	-7.3
Operating profit	3.7	5.7	4.0	5.7	5.7	7.5	-28.9
OP margin (%)	14.4	19.1	14.6	18.8	18.7	0.2	-4.4
Pretax profit	1.8	5.8	3.4	5.7	5.0	92.3	-40.8
Net profit	3.9	4.5	2.3	5.2	4.4	-41.2	-48.5

Notes: Based on consolidated K-IFRS; net profit is attributable to controlling interests

Source: FnGuide, company data, Mirae Asset Daewoo Research estimates

Table 2. Earnings forecast revisions

Previous Revised % chg. Notes 19F 20F 19F 20F 19F 20F Revenue 138.0 154.2 133.6 147.4 -3.2 -4.4 Reflecting 4Q18 earnings Operating profit 27.5 30.9 26.5 29.7 -3.7 -4.2 Pretax profit 27.6 31.4 26.5 30.1 -3.8 -4.2 Net profit 22.6 25.7 21.8 24.7 -3.8 -4.2 1,363.5 -4.2 EPS (W) 1,551.3 1,312.2 1,486.4 -3.8

Notes: Based on consolidated K-IFRS; net profit is attributable to controlling interests

Source: Company data, Mirae Asset Daewoo Research estimates

Table 3. Quarterly and annual earnings

Table 3. Quarterly and annual earnings(W											
	1Q18	2Q18	3Q18	4Q18P	1Q19F	2Q19F	3Q19F	4Q19F	2018P	2019F	2020F
Revenue	28.5	30.7	29.7	27.5	32.3	35.0	36.1	30.2	116.4	133.6	147.4
TFT	12.2	14.5	12.6	14.4	13.4	15.3	13.2	14.8	53.7	56.7	59.7
CMOS	10.0	11.7	14.1	6.3	11.5	13.2	14.8	7.6	42.1	47.0	52.0
Other	10.1	8.7	9.3	9.5	91.5	105.1	119.4	140.1	37.7	43.6	50.8
Operating profit	5.2	6.4	5.7	4.0	6.4	7.0	7.2	5.8	21.2	26.5	29.7
Pretax profit	5.4	7.2	5.8	3.4	6.4	7.0	7.3	5.9	21.9	26.5	30.1
Net profit	4.6	5.6	4.5	2.3	5.2	5.8	5.9	4.8	17.0	21.8	24.7
OP margin	18.2	20.7	19.1	14.6	19.8	20.0	20.1	19.3	18.2	19.8	20.1
Pretax margin	19.1	23.3	19.6	12.5	19.8	20.0	20.1	19.5	18.8	19.9	20.4
Net margin	16.1	18.1	14.9	8.1	16.2	16.4	16.5	16.0	14.6	16.3	16.7

Source: Company data, Mirae Asset Daewoo Research estimates

19.0x

16.0x

(Wbn)

Figure 1. Ownership structure





Figure 3. 12-month forward P/E band

Figure 2. Domestic institutional and foreign net buying



(W) 30,000 25,000 20,000




Table 4. Global peer valuation


Companies	Market	OP r	nargin (^e	%)		P/E (x)		l	P/B (x)		F	ROE (%)		EV/I	EBITDA (X)
companies	сар	17	18F	19F	17	18F	19F	17	18F	19F	17	18F	19F	17	18F	19F
Dentsply Sirona	10,445	-39.1	15.3	16.9	26.5	21.3	19.2	2.4	2.4	2.3	-26.4	7.8	9.7	-	14.2	13.0
GE	98,872	-16.7	9.1	10.4	17.6	13.3	12.1	0.7	0.7	0.8	-61.7	14.6	20.1	-	10.9	9.8
Siemens Healthineers	44,061	14.6	17.8	18.7	26.5	20.3	18.7	2.5	2.4	2.3	20.9	18.1	18.0	16.1	13.1	12.1
Canon	43,093	8.7	8.3	8.3	13.4	14.4	14.3	0.9	1.1	1.1	8.9	8.0	8.2	5.6	7.5	7.5
Koninklijke Philips	40,858	9.5	13.0	14.2	24.4	18.8	15.9	1.8	1.7	1.6	9.1	13.0	14.4	11.0	10.4	9.4
Fujifilm Holdings	24,512	5.4	8.2	9.6	14.8	14.8	12.4	0.8	1.0	0.9	6.4	6.2	6.8	8.3	7.6	6.7
Hologic	14,471	-7.4	29.2	29.9	36.2	18.4	16.9	3.7	3.9	3.8	-15.0	23.7	22.5	55.4	14.5	13.6
Varex Imaging	1,215	5.8	11.9	13.2	28.7	22.3	18.4	1.4	1.4	1.4	6.8	11.5	10.5	16.6	12.3	10.7
Agfa Gevaert	755	5.7	-	-	-	11.4	10.0	0.3	0.3	0.3	6.0	11.1	10.5	4.1	4.0	3.8
Vieworks	346	23.2	17.6	20.1	17.8	16.4	13.7	2.7	2.6	2.3	14.8	15.2	16.0	10.3	10.8	8.6
Rayence	255	16.2	19.1	19.9	13.4	13.4	11.7	2.2	2.1	1.8	10.5	10.4	11.1	8.1	6.1	5.3
Average		2.3	15.0	16.1	22.0	16.8	14.8	1.8	1.8	1.7	-1.8	12.7	13.4	15.1	10.1	9.2

Source: Bloomberg, Mirae Asset Daewoo Research

Source: Bloomberg, Mirae Asset Daewoo Research

Source: Mirae Asset Daewoo Research

Source: Mirae Asset Daewoo Research



Source: Company data, Mirae Asset Daewoo Research






Figure 6. Revenue breakdown by product

Source: Company data, Mirae Asset Daewoo Research




Source: Company data, Mirae Asset Daewoo Research

Figure 8. Revenue breakdown by country



Source: Mirae Asset Daewoo Research

Figure 9. Revenue trend by country



Source: Mirae Asset Daewoo Research

Figure 7. Revenue trend by product

Rayence (228850 KQ/Buy/TP: W22,000)

Comprehensive Income Statement (Summarized)

40/47	42/405	42/405	42/205
	-		12/20F
107	116	134	147
66	72	81	89
41	44	53	58
23	23	26	29
17	21	26	30
17	21	26	30
-2	1	1	0
1	1	1	2
0	0	0	0
15	22	27	30
0	5	5	5
14	17	22	25
0	0	0	0
14	17	22	25
15	17	22	25
0	0	0	0
15	17	22	25
15	17	22	25
0	0	0	0
24	28	33	35
16	10	23	25
22.4	24.1	24.6	23.8
15.9	18.1	19.4	20.4
14.0	14.7	16.4	17.0
	41 23 17 17 -2 1 0 15 0 14 15 0 14 15 0 15 15 0 24 16 224 15.9	107 116 66 72 41 44 23 23 17 21 17 21 -2 1 1 1 0 0 15 22 0 5 14 17 0 0 14 17 0 0 14 17 0 0 15 17 0 0 24 28 16 10 22.4 24.1 15.9 18.1	107 116 134 66 72 81 41 44 53 23 23 26 17 21 26 17 21 26 17 21 26 17 21 26 17 21 26 17 21 26 10 0 0 11 1 1 1 0 0 0 0 15 22 27 0 0 0 0 0 14 17 22 0 0 0 0 0 14 17 22 0 0 15 17 22 0 0 15 17 22 0 0 24 28 33 16 10 23 22.4 24.1 24.6 15.9 <t< td=""></t<>

Statement of Financial Condition (Summarized)

(Wbn)	12/17	12/18F	12/19F	12/20F
Current Assets	141	148	176	206
Cash and Cash Equivalents	21	21	37	55
AR & Other Receivables	19	32	35	39
Inventories	27	26	28	31
Other Current Assets	74	69	76	81
Non-Current Assets	56	54	47	42
Investments in Associates	0	0	0	0
Property, Plant and Equipment	34	32	28	25
Intangible Assets	20	21	18	15
Total Assets	196	202	224	248
Current Liabilities	18	15	17	18
AP & Other Payables	9	10	11	12
Short-Term Financial Liabilities	5	2	2	2
Other Current Liabilities	4	3	4	4
Non-Current Liabilities	2	1	2	2
Long-Term Financial Liabilities	0	0	0	0
Other Non-Current Liabilities	2	1	2	2
Total Liabilities	19	17	18	20
Controlling Interests	177	185	205	228
Capital Stock	8	8	8	8
Capital Surplus	108	108	108	108
Retained Earnings	68	83	103	126
Non-Controlling Interests	0	0	0	0
Stockholders' Equity	177	185	205	228

Cash Flows (Summarized)

(Wbn)	12/17	12/18F	12/19F	12/20F
Cash Flows from Op Activities	21	11	23	25
Net Profit	14	17	22	25
Non-Cash Income and Expense	11	12	10	9
Depreciation	3	4	3	3
Amortization	3	3	3	3
Others	5	5	4	3
Chg in Working Capital	-4	-15	-5	-6
Chg in AR & Other Receivables	3	-14	-3	-4
Chg in Inventories	-3	2	-3	-3
Chg in AP & Other Payables	-1	0	1	1
Income Tax Paid	-2	-3	-5	-5
Cash Flows from Inv Activities	-3	2	-5	-6
Chg in PP&E	-5	-1	0	0
Chg in Intangible Assets	-5	-4	0	0
Chg in Financial Assets	7	6	-5	-6
Others	0	1	0	0
Cash Flows from Fin Activities	-6	-12	-2	-2
Chg in Financial Liabilities	-2	-3	0	0
Chg in Equity	0	0	0	0
Dividends Paid	-2	-2	-2	-2
Others	-2	-7	0	0
Increase (Decrease) in Cash	12	0	16	17
Beginning Balance	9	21	21	37
Ending Balance	21	21	37	55

Source: Company data, Mirae Asset Daewoo Research estimates

Forecasts/Valuations (Summarized)

	12/17	12/18F	12/19F	12/20F
P/E (x)	21.0	16.0	11.7	10.4
P/CF (x)	12.1	9.5	8.1	7.5
P/B (x)	1.7	1.4	1.2	1.1
EV/EBITDA (x)	9.5	6.8	4.6	3.7
EPS (W)	881	1,023	1,312	1,486
CFPS (W)	1,531	1,718	1,907	2,051
BPS (W)	11,086	11,988	13,205	14,597
DPS (W)	100	100	100	100
Payout ratio (%)	11.2	9.4	7.2	6.4
Dividend Yield (%)	0.5	0.6	0.6	0.6
Revenue Growth (%)	9.2	8.4	15.5	9.7
EBITDA Growth (%)	4.3	16.7	17.9	6.1
Operating Profit Growth (%)	-5.6	23.5	23.8	15.4
EPS Growth (%)	-7.0	16.1	28.3	13.3
Accounts Receivable Turnover (x)	5.3	4.6	3.9	4.0
Inventory Turnover (x)	4.1	4.4	4.9	5.0
Accounts Payable Turnover (x)	9.1	10.6	11.1	11.1
ROA (%)	7.4	8.4	10.2	10.5
ROE (%)	8.5	9.4	11.2	11.4
ROIC (%)	18.2	16.3	20.9	23.5
Liability to Equity Ratio (%)	11.0	9.1	8.9	8.7
Current Ratio (%)	799.5	964.6	1,058.5	1,141.0
Net Debt to Equity Ratio (%)	-47.7	-44.1	-50.4	-55.4
Interest Coverage Ratio (x)	28.3	106.6	185.7	208.0

Feb 19

Feb 18

APPENDIX 1

Important Disclosures & Disclaimers

2-Year Rating and Target Price History

Date	Rating	Target Price	(14/)	_
11/04/2018	Buy	22,000		Rayence
01/25/2018	Buy	26,000		
05/03/2017	Buy	24,000		
04/11/2017	Buy	22,000	20,000	the hard and the the and the former and the server
			15,000	- Your the
			10,000	-
	11/04/2018 01/25/2018 05/03/2017	11/04/2018 Buy 01/25/2018 Buy 05/03/2017 Buy	11/04/2018 Buy 22,000 01/25/2018 Buy 26,000 05/03/2017 Buy 24,000	11/04/2018 Buy 22,000 30,000 01/25/2018 Buy 26,000 25,000 05/03/2017 Buy 24,000 20,000 04/11/2017 Buy 22,000 15,000

5 000

Feb 17

Stock Rating	S	Industry Ratings				
Buy	: Relative performance of 20% or greater	Overweight	: Fundamentals are favorable or improving			
Trading Buy	: Relative performance of 10% or greater, but with volatility	Neutral	: Fundamentals are steady without any material changes			
Hold	: Relative performance of -10% and 10%	Underweight	: Fundamentals are unfavorable or worsening			
Sell	: Relative performance of -10%					

Ratings and Target Price History (Share price (–), Target price (–), Not covered (=), Buy (▲), Trading Buy (■), Hold (•), Sell (♠))

* Our investment rating is a guide to the relative return of the stock versus the market over the next 12 months.

* Although it is not part of the official ratings at Mirae Asset Daewoo Co., Ltd., we may call a trading opportunity in case there is a technical or short-term material development.

* The target price was determined by the research analyst through valuation methods discussed in this report, in part based on the analyst's estimate of future earnings.

* The achievement of the target price may be impeded by risks related to the subject securities and companies, as well as general market and economic conditions.

Equity Ratings Distribution & Investment Banking Services

	Buy	Trading Buy	Hold	Sell			
Equity Ratings Distribution	81.28%	9.63%	9.09%	0.00%			
Investment Banking Services	84.61%	3.85%	11.54%	0.00%			
* Pased on recommendations in the last 12 menths (as of December 21, 2019)							

* Based on recommendations in the last 12-months (as of December 31, 2018)

Disclosures

As of the publication date, Mirae Asset Daewoo Co., Ltd. is acting as a financial advisor to Rayence for its treasury share buyback and cancellation.

Analyst Certification

The research analysts who prepared this report (the "Analysts") are registered with the Korea Financial Investment Association and are subject to Korean securities regulations. They are neither registered as research analysts in any other jurisdiction nor subject to the laws or regulations thereof. Each Analyst responsible for the preparation of this report certifies that (i) all views expressed in this report accurately reflect the personal views of the Analyst about any and all of the issuers and securities named in this report and (ii) no part of the compensation of the Analyst was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report. Mirae Asset Daewoo Co., Ltd. ("Mirae Asset Daewoo") policy prohibits its Analysts and members of their households from owning securities of any company in the Analyst's area of coverage, and the Analysts do not serve as an officer, director or advisory board member of the subject companies. Except as otherwise specified herein, the Analysts have not received any compensation or any other benefits from the subject companies in the past 12 months and have not been promised the same in connection with this report. Like all employees of Mirae Asset Daewoo, the Analysts receive compensation that is determined by overall firm profitability, which includes revenues from, among other business units, the institutional equities, investment banking, proprietary trading and private client division. At the time of publication of this report, the Analysts do not know or have reason to know of any actual, material conflict of interest of the Analyst or Mirae Asset Daewoo except as otherwise stated herein.

Disclaimers

This report was prepared by Mirae Asset Daewoo, a broker-dealer registered in the Republic of Korea and a member of the Korea Exchange. Information and opinions contained herein have been compiled in good faith and from sources believed to be reliable, but such information has not been independently verified and Mirae Asset Daewoo makes no guarantee, representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the information and opinions contained herein or of any translation into English from the Korean language. In case of an English translation of a report prepared in the Korean language, the original Korean language report may have been made available to investors in advance of this report.

The intended recipients of this report are sophisticated institutional investors who have substantial knowledge of the local business environment, its common practices, laws and accounting principles and no person whose receipt or use of this report would violate any laws or regulations or subject Mirae Asset Daewoo or any of its affiliates to registration or licensing requirements in any jurisdiction shall receive or make any use hereof.

This report is for general information purposes only and it is not and shall not be construed as an offer or a solicitation of an offer to effect transactions in any securities or other financial instruments. The report does not constitute investment advice to any person and such person shall not be treated as a client of Mirae Asset Daewoo by virtue of receiving this report. This report does not take into account the particular investment objectives, financial situations, or needs of individual clients. The report is not to be relied upon in substitution for the exercise of independent judgment. Information and

opinions contained herein are as of the date hereof and are subject to change without notice. The price and value of the investments referred to in this report and the income from them may depreciate or appreciate, and investors may incur losses on investments. Past performance is not a guide to future performance. Future returns are not guaranteed, and a loss of original capital may occur. Mirae Asset Daewoo, its affiliates and their directors, officers, employees and agents do not accept any liability for any loss arising out of the use hereof.

Mirae Asset Daewoo may have issued other reports that are inconsistent with, and reach different conclusions from, the opinions presented in this report. The reports may reflect different assumptions, views and analytical methods of the analysts who prepared them. Mirae Asset Daewoo may make investment decisions that are inconsistent with the opinions and views expressed in this research report. Mirae Asset Daewoo, its affiliates and their directors, officers, employees and agents may have long or short positions in any of the subject securities at any time and may make a purchase or sale, or offer to make a purchase or sale, of any such securities or other financial instruments from time to time in the open market or otherwise, in each case either as principals or agents. Mirae Asset Daewoo and its affiliates may have had, or may be expecting to enter into, business relationships with the subject companies to provide investment banking, market-making or other financial services as are permitted under applicable laws and regulations. No part of this document may be copied or reproduced in any manner or form or redistributed or published, in whole or in part, without the prior written

No part of this document may be copied or reproduced in any manner or form or redistributed or published, in whole or in part, without the prior written consent of Mirae Asset Daewoo.

Distribution

<u>United Kingdom</u>: This report is being distributed by Mirae Asset Securities (UK) Ltd. in the United Kingdom only to (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (ii) high net worth companies and other persons to whom it may lawfully be communicated, falling within Article 49(2)(A) to (E) of the Order (all such persons together being referred to as "Relevant Persons"). This report is directed only at Relevant Persons. Any person who is not a Relevant Person should not act or rely on this report or any of its contents.

<u>United States</u>: Mirae Asset Daewoo is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This report is distributed in the U.S. by Mirae Asset Securities (USA) Inc., a member of FINRA/SIPC, to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6(b)(4) under the U.S. Securities Exchange Act of 1934, as amended. All U.S. persons that receive this document by their acceptance hereof represent and warrant that they are a major U.S. institutional investor and have not received this report under any express or implied understanding that they will direct commission income to Mirae Asset Daewoo or its affiliates. Any U.S. recipient of this document wishing to effect a transaction in any securities discussed herein should contact and place orders with Mirae Asset Securities (USA) Inc. Mirae Asset Securities (USA) Inc. accepts responsibility for the contents of this report in the U.S. subject to the etrms hereof, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. Under no circumstances should any recipient of this report may not have been registered under the U.S. Securities Act of 1933, as amended, and, in such case, may not be offered or sold in the U.S. or to U.S. persons absent registration or an applicable exemption from the registration requirements.

Hong Kong: This report is distributed in Hong Kong by Mirae Asset Securities (HK) Limited, which is regulated by the Hong Kong Securities and Futures Commission. The contents of this report have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule 1 to the Securities and Futures Ordinance of Hong Kong (Cap. 571, Laws of Hong Kong) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person.

<u>All Other Jurisdictions</u>: Customers in all other countries who wish to effect a transaction in any securities referenced in this report should contact Mirae Asset Daewoo or its affiliates only if distribution to or use by such customer of this report would not violate applicable laws and regulations and not subject Mirae Asset Daewoo and its affiliates to any registration or licensing requirement within such jurisdiction.

Mirae Asset Daewoo International Network

Mirae Asset Daewoo Co., Ltd. (Seoul)

Global Equity Sales Team Mirae Asset Center 1 Building 26 Eulji-ro 5-gil, Jung-gu, Seoul 04539 Korea

Tel: 82-2-3774-2124

Mirae Asset Securities (USA) Inc.

810 Seventh Avenue, 37th Floor New York, NY 10019 USA

Tel: 1-212-407-1000

PT. Mirae Asset Sekuritas Indonesia

Equity Tower Building Lt. 50 Sudirman Central Business District Jl. Jend. Sudirman, Kav. 52-53 Jakarta Selatan 12190 Indonesia Tel: 62-21-515-3281

Mirae Asset Securities Mongolia UTsK LLC

#406, Blue Sky Tower, Peace Avenue 17 1 Khoroo, Sukhbaatar District Ulaanbaatar 14240 Mongolia

Tel: 976-7011-0806

Shanghai Representative Office

38T31, 38F, Shanghai World Financial Center 100 Century Avenue, Pudong New Area Shanghai 200120 China

Tel: 86-21-5013-6392

Mirae Asset Securities (HK) Ltd.

Suites 1109-1114, 11th Floor Two International Finance Centre 8 Finance Street, Central Hong Kong China Tel: 852-2845-6332

Mirae Asset Wealth Management (USA) Inc.

555 S. Flower Street, Suite 4410, Los Angeles, California 90071

Tel: 1-213-262-3807

USA

Mirae Asset Securities (Singapore) Pte. Ltd. 6 Battery Road, #11-01 Singapore 049909 Republic of Singapore

Tel: 65-6671-9845

Mirae Asset Investment Advisory (Beijing) Co., Ltd

2401B, 24th Floor, East Tower, Twin Towers B12 Jianguomenwai Avenue, Chaoyang District Beijing 100022 China

Tel: 86-10-6567-9699

Ho Chi Minh Representative Office

7F, Saigon Royal Building 91 Pasteur St. District 1, Ben Nghe Ward, Ho Chi Minh City Vietnam

Tel: 84-8-3910-7715

Mirae Asset Securities (UK) Ltd. 41st Floor, Tower 42

25 Old Broad Street, London EC2N 1HQ United Kingdom

Tel: 44-20-7982-8000

Mirae Asset Wealth Management (Brazil) CCTVM

Rua Funchal, 418, 18th Floor, E-Tower Building Vila Olimpia Sao Paulo - SP 04551-060 Brasil Tel: 55-11-2789-2100

Mirae Asset Securities (Vietnam) LLC

7F, Saigon Royal Building 91 Pasteur St. District 1, Ben Nghe Ward, Ho Chi Minh City Vietnam

Tel: 84-8-3911-0633 (ext.110)

Beijing Representative Office

2401A, 24th Floor, East Tower, Twin Towers B12 Jianguomenwai Avenue, Chaoyang District Beijing 100022 China

Tel: 86-10-6567-9699 (ext. 3300)